Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.64 |
| ▸ | MET | P08581 | 9/20 | 0.62 |
| ▸ | AXL | P30530 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253736 | 0.91 | JAK2 (0.73) | JAK2ALKMETAXL | |
| SCHEMBL5252787 | 0.90 | JAK2 (0.82) | JAK2ALKMETAXL | |
| SCHEMBL5252602 | 0.87 | JAK2 (0.78) | JAK2ALKMETAXL | |
| SCHEMBL21478600 | 0.86 | JAK2 (1.00) | JAK2ALKMETAXL | |
| SCHEMBL5253930 | 0.86 | JAK2 (0.81) | JAK2ALKMET | |
| SCHEMBL5255032 | 0.86 | JAK2 (1.00) | JAK2ALKMETAXL | |
| SCHEMBL3117117 | 0.82 | JAK2 (0.75) | JAK2ALKMETAXL | |
| SCHEMBL10216533 | 0.81 | MET (0.70) | JAK2ALKMETAXL | |
| SCHEMBL16562971 | 0.81 | JAK2 (0.90) | JAK2ALKMETAXL | |
| SCHEMBL16562982 | 0.81 | JAK2 (0.90) | JAK2ALKMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786777-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | JAK2 342/4885ALK 100/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.